Q4:公司中药创新药目前处于什么阶段？预计何时能够提交 上市申请？ 证券代码： 002864 证券简称：盘龙药业 陕西盘龙药业集团股份有限公司投资者关系活动记录表 编号：2025-008 | 投资者关系活动 □ | 特定对象调研 □ 分析师会议 | | --- | --- | | 类别 □ | 媒体采访 □ 业绩说明会 | | □ | 新闻发布会 ☑ 路演活动 | | □ | 现场参观 | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 线上参加交流的投资者 | | 人员姓名 | | | 时间 | 2025 年 9 月 10 日 | | 地点 | 同花顺路演平台 | | 上市公司接待人 | 董事长谢晓林先生，董事会秘书吴杰先生，独立董事任海云女士， | | 员姓名 | 独立董事牛晓峰先生，董事、副总裁、研究院院长张德柱先生， | | | 财务总监祝凤鸣先生 | | | 投资者提出的问题及公司回复情况 | | | Q1：中药配方颗粒业务收入规模较小，何时能成为第二增长 | | | 曲线？ | | | A：尊敬的投资者您好！公司已于 2024 年年末完成了中药配 | | | 方颗粒智能化 ...

Core Insights - The company reported a strong performance for the first half of 2025, achieving revenue of 574 million yuan, a year-on-year increase of 26.06%, and a net profit of 60.14 million yuan, up 0.81% [2][3] - The growth is attributed to the implementation of the "one body, two wings, three depths" strategy, focusing on orthopedic chronic diseases and enhancing brand integration and innovation in traditional Chinese medicine [2][3] Revenue and Profitability - The company's self-produced traditional Chinese medicine generated revenue of 319 million yuan, contributing 55.5% to total revenue, with a gross margin of 87.26% [3] - The Chinese herbal pieces business saw a remarkable growth of 380.89%, reaching 123 million yuan in revenue, making it the fastest-growing product line [3] Marketing and Distribution - The company has transformed its marketing system, covering over 5,000 medical institutions and tens of thousands of retail terminals, establishing a dual-driven model of "medical + retail" [3] - The company has built a network of over 650 commercial partners across 30 provincial-level administrative regions, enhancing its sales channels [3] Product Development and Innovation - The company invested 15.85 million yuan in R&D during the first half of 2025, a year-on-year increase of 11.18%, focusing on innovative drugs and traditional Chinese medicine [7][8] - The number of registered traditional Chinese medicine formula granules has increased to 310, indicating a strong pipeline for future growth [7] Core Product Performance - The core product, Panlong Qipian, maintained a strong market position with a market share of 7.73% in the orthopedic and rheumatic disease sector [5] - Panlong Qipian has been recognized in multiple national clinical guidelines and has received various accolades, enhancing its brand influence [6] Financial Returns to Shareholders - The company plans to distribute a cash dividend of 1 yuan per 10 shares to shareholders, totaling approximately 10.59 million yuan [4] Investment and Capital Operations - The company is actively engaging in investment activities, with significant progress in its industrial fund projects, particularly in the development of innovative drug delivery systems [9] - The company aims to integrate its capital operations with its core business to drive high-quality development [9]

Core Viewpoint - The financial report of Shanxi Panlong Pharmaceutical Group Co., Ltd. for 2024 shows a slight decline in revenue but a significant increase in net profit, indicating a stable growth trajectory since its listing in 2017 [1] Group 1: Financial Performance - The company's operating income for 2024 was 974 million yuan, a year-on-year decrease of 0.7% [1] - The net profit attributable to shareholders was 120 million yuan, reflecting an 8.9% year-on-year increase [1] - This marks the eighth consecutive year of net profit growth since the company went public [1] Group 2: Strategic Development - The company has implemented a strategic framework termed "One Body, Two Wings, Three Depths," focusing on orthopedic chronic diseases and leveraging national policies supporting traditional Chinese medicine [1][2] - The strategy includes enhancing governance and optimizing innovation across research, production, and sales [1][2] Group 3: Market Position and Growth Opportunities - Panlong Pharmaceutical has established a full industry chain encompassing medicinal herb planting, drug research, production, and sales [2] - The market share of its core product, Panlong Seven Tablets, continues to expand, and the traditional Chinese medicine segment is experiencing rapid growth [2] - The company has obtained research filing for 211 varieties of traditional Chinese medicine formula granules, laying the groundwork for new revenue streams [2] Group 4: Innovation and Collaboration - The company is responding to national policies by accelerating product innovation and has established a joint venture for new drug research with another pharmaceutical company [2][3] - The new research platform aims to enhance the company's capabilities in developing innovative drugs, particularly focusing on chronic disease treatments [3] Group 5: Future Growth Strategy - The company plans to leverage its established industry foundation for external growth through mergers and acquisitions, aiming to enhance its strategic positioning [3] - The dual strategy of "innovation development + merger expansion + integrated industry chain" is designed to adapt to market changes and drive new growth engines [3]